Cargando…

Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group

This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each In...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiromitsu, Ishikawa, Hitoshi, Takagi, Masaru, Okimoto, Tomoaki, Murayama, Sigeyuki, Akimoto, Tetsuo, Wada, Hitoshi, Arimura, Takeshi, Sato, Yoshitaka, Araya, Masayuki, Mizoe, Jun‐etsu, Gosho, Masahiko, Nakamura, Katsumasa, Shirato, Hiroki, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852348/
https://www.ncbi.nlm.nih.gov/pubmed/29441697
http://dx.doi.org/10.1002/cam4.1350
_version_ 1783306553270468608
author Iwata, Hiromitsu
Ishikawa, Hitoshi
Takagi, Masaru
Okimoto, Tomoaki
Murayama, Sigeyuki
Akimoto, Tetsuo
Wada, Hitoshi
Arimura, Takeshi
Sato, Yoshitaka
Araya, Masayuki
Mizoe, Jun‐etsu
Gosho, Masahiko
Nakamura, Katsumasa
Shirato, Hiroki
Sakurai, Hideyuki
author_facet Iwata, Hiromitsu
Ishikawa, Hitoshi
Takagi, Masaru
Okimoto, Tomoaki
Murayama, Sigeyuki
Akimoto, Tetsuo
Wada, Hitoshi
Arimura, Takeshi
Sato, Yoshitaka
Araya, Masayuki
Mizoe, Jun‐etsu
Gosho, Masahiko
Nakamura, Katsumasa
Shirato, Hiroki
Sakurai, Hideyuki
author_sort Iwata, Hiromitsu
collection PubMed
description This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (bRFS) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the NCCN classification was a significant prognostic factor for bRFS, but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (UMIN000025453) on PT for prostate cancer has just been initiated in order to define its role in Japan.
format Online
Article
Text
id pubmed-5852348
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58523482018-03-22 Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group Iwata, Hiromitsu Ishikawa, Hitoshi Takagi, Masaru Okimoto, Tomoaki Murayama, Sigeyuki Akimoto, Tetsuo Wada, Hitoshi Arimura, Takeshi Sato, Yoshitaka Araya, Masayuki Mizoe, Jun‐etsu Gosho, Masahiko Nakamura, Katsumasa Shirato, Hiroki Sakurai, Hideyuki Cancer Med Clinical Cancer Research This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (bRFS) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the NCCN classification was a significant prognostic factor for bRFS, but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (UMIN000025453) on PT for prostate cancer has just been initiated in order to define its role in Japan. John Wiley and Sons Inc. 2018-02-14 /pmc/articles/PMC5852348/ /pubmed/29441697 http://dx.doi.org/10.1002/cam4.1350 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Iwata, Hiromitsu
Ishikawa, Hitoshi
Takagi, Masaru
Okimoto, Tomoaki
Murayama, Sigeyuki
Akimoto, Tetsuo
Wada, Hitoshi
Arimura, Takeshi
Sato, Yoshitaka
Araya, Masayuki
Mizoe, Jun‐etsu
Gosho, Masahiko
Nakamura, Katsumasa
Shirato, Hiroki
Sakurai, Hideyuki
Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title_full Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title_fullStr Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title_full_unstemmed Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title_short Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group
title_sort long‐term outcomes of proton therapy for prostate cancer in japan: a multi‐institutional survey of the japanese radiation oncology study group
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852348/
https://www.ncbi.nlm.nih.gov/pubmed/29441697
http://dx.doi.org/10.1002/cam4.1350
work_keys_str_mv AT iwatahiromitsu longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT ishikawahitoshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT takagimasaru longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT okimototomoaki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT murayamasigeyuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT akimototetsuo longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT wadahitoshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT arimuratakeshi longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT satoyoshitaka longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT arayamasayuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT mizoejunetsu longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT goshomasahiko longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT nakamurakatsumasa longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT shiratohiroki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup
AT sakuraihideyuki longtermoutcomesofprotontherapyforprostatecancerinjapanamultiinstitutionalsurveyofthejapaneseradiationoncologystudygroup